Vitamin D Supplementation and Antibiotic Use in Older Australian Adults: An Analysis of Data From the D-Health Trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

The researchers analyzed data from the D-Health Trial, using prescription of antibiotics as a surrogate for infection.

Who Took Part

By PubMed's age tags, the people studied were adults and older adults.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

For this analysis, the primary outcome was the number of antibiotic prescription episodes; secondary outcomes were total number of prescriptions, repeat prescription episodes, and antibiotics for urinary tract infection.

What Was Measured

PubMed files the paper under topics including Anti-Bacterial Agents, Australia, Cholecalciferol, Dietary Supplements, Vitamin D and Vitamins.

The authors tagged it with the keywords antibiotic use, randomized controlled trial, urinary tract infection and vitamin D supplementation.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (The Journal of infectious diseases), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.